{ "meta": { "data_length": 2, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A93", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004214, "timestamp_received": "2026-09-25T00:14:19.419784+00:00Z", "timestamp_returned": "2026-09-25T00:14:19.423998+00:00Z", "trace_id": "1d48f8f0-8622-482c-9126-402ad16af3fa" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:tafinlar:5:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-06-22:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2022-06-22", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:tafinlar", "type": "Document", "documentType": "Regulatory approval", "name": "Tafinlar (dabrafenib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tafinlar", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "dabrafenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 202806, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:93", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C132146", "conceptType": "Disease", "name": "Any solid tumor", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146" ] } }, "objectTherapeutic": { "id": "txgrp:18", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C82386", "conceptType": "Therapy", "name": "Dabrafenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1424911", "code": "1424911", "name": "dabrafenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1424911" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532299", "code": "43532299", "name": "dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532299" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:703641001", "code": "703641001", "name": "Dabrafenib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=703641001&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45766476", "code": "45766476", "name": "Dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45766476" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "B-RAF inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386" ] } }, { "id": "tx:ncit:C77908", "conceptType": "Therapy", "name": "Trametinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1425099", "code": "1425099", "name": "trametinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1425099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532497", "code": "43532497", "name": "trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532497" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:708711009", "code": "708711009", "name": "Trametinib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=708711009&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:46270750", "code": "46270750", "name": "Trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/46270750" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "MEK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:16", "present": true, "subject": { "id": "bmkr:16", "type": "CategoricalVariant", "name": "BRAF p.V600E", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "name": "NP_004324.2:p.Val600Glu", "aliases": [ "NP_004324.2:p.V600E", "BRAF p.V600E" ], "description": "VRS variation of NP_004324.2:p.Val600Glu", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "expressions": [ { "syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu", "extensions": [ { "name": "hgvs.p_short", "value": "p.V600E" } ] } ], "location": { "id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": { "id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "type": "SequenceReference", "name": "NP_004324.2", "aliases": [ "ensembl:ENSP00000288602.6", "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "refseq:NP_004324.2" ], "description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.", "moleculeType": "protein", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "residueAlphabet": "aa" }, "start": 599, "end": 600, "sequence": "V" }, "state": { "type": "LiteralSequenceExpression", "sequence": "E" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1097", "conceptType": "Gene", "name": "BRAF", "primaryCoding": { "id": "coding:hgnc:1097", "code": "HGNC:1097", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157764", "code": "ENSG00000157764", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157764" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:673", "code": "673", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/673" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004333.6", "code": "NM_004333.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 140453136 }, { "name": "end_position", "value": 140453136 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.1799T>A" }, { "name": "protein_change", "value": "p.V600E" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 15 }, { "name": "rsid", "value": "rs113488022" }, { "name": "hgvsg", "value": "7:g.140453136A>T" }, { "name": "hgvsc", "value": "ENST00000288602.6:c.1799T>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:tafinlar:5", "type": "Indication", "description": "TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-06-22:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2022-06-22", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:tafinlar", "type": "Document", "documentType": "Regulatory approval", "name": "Tafinlar (dabrafenib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tafinlar", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "dabrafenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 202806, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] }, { "id": "stmt:fda:mekinist:5:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted accelerated approval to trametinib in combination with dabrafenib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. The product label specifies that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, the product label states a Limitation of Use: trametinib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:fda:mekinist", "type": "Document", "documentType": "Regulatory approval", "name": "Mekinist (trametinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Mekinist", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "trametinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 217513, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:93", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C132146", "conceptType": "Disease", "name": "Any solid tumor", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146" ] } }, "objectTherapeutic": { "id": "txgrp:18", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C82386", "conceptType": "Therapy", "name": "Dabrafenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1424911", "code": "1424911", "name": "dabrafenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1424911" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532299", "code": "43532299", "name": "dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532299" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:703641001", "code": "703641001", "name": "Dabrafenib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=703641001&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45766476", "code": "45766476", "name": "Dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45766476" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "B-RAF inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386" ] } }, { "id": "tx:ncit:C77908", "conceptType": "Therapy", "name": "Trametinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1425099", "code": "1425099", "name": "trametinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1425099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532497", "code": "43532497", "name": "trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532497" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:708711009", "code": "708711009", "name": "Trametinib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=708711009&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:46270750", "code": "46270750", "name": "Trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/46270750" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "MEK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:16", "present": true, "subject": { "id": "bmkr:16", "type": "CategoricalVariant", "name": "BRAF p.V600E", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "name": "NP_004324.2:p.Val600Glu", "aliases": [ "NP_004324.2:p.V600E", "BRAF p.V600E" ], "description": "VRS variation of NP_004324.2:p.Val600Glu", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "expressions": [ { "syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu", "extensions": [ { "name": "hgvs.p_short", "value": "p.V600E" } ] } ], "location": { "id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": { "id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "type": "SequenceReference", "name": "NP_004324.2", "aliases": [ "ensembl:ENSP00000288602.6", "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "refseq:NP_004324.2" ], "description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.", "moleculeType": "protein", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "residueAlphabet": "aa" }, "start": 599, "end": 600, "sequence": "V" }, "state": { "type": "LiteralSequenceExpression", "sequence": "E" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1097", "conceptType": "Gene", "name": "BRAF", "primaryCoding": { "id": "coding:hgnc:1097", "code": "HGNC:1097", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157764", "code": "ENSG00000157764", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157764" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:673", "code": "673", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/673" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004333.6", "code": "NM_004333.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 140453136 }, { "name": "end_position", "value": 140453136 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.1799T>A" }, { "name": "protein_change", "value": "p.V600E" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 15 }, { "name": "rsid", "value": "rs113488022" }, { "name": "hgvsg", "value": "7:g.140453136A>T" }, { "name": "hgvsc", "value": "ENST00000288602.6:c.1799T>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:mekinist:5", "type": "Indication", "description": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Limitations of Use: MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:fda:mekinist", "type": "Document", "documentType": "Regulatory approval", "name": "Mekinist (trametinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Mekinist", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "trametinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 217513, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }